Mesenchymal stem cells (MSCs) are used in both human clinical trials and veterinary medicine for the treatment of inflammatory and immune-mediated diseases. MSCs modulate inflammation by decreasing the cells and products of the inflammatory response. Stimulated equine MSCs from bone marrow (BM), adipose tissue (AT), cord blood (CB), and umbilical cord tissue (CT) inhibit lymphocyte proliferation and decrease inflammatory cytokine production. We hypothesized that equine MSCs inhibit T cell proliferation through secreted mediators and that MSCs from different tissue sources decrease T cell proliferation through different mechanisms. To test our hypotheses, we inhibited interleukin-6 (IL-6), nitric oxide (NO), and prostaglandin E2 (PGE2) to determine their impact on stimulated T cell proliferation. We also determined how equine MSCs modulate lymphocyte proliferation either via cell cycle arrest or apoptosis. Inhibition of IL-6 or NO did not reverse the immunomodulatory effect of MSCs on activated T cells. In contrast, inhibition of PGE2 restored T cell proliferation, restored the secretion of tumor necrosis factor-α and interferon-γ, and increased IL-10 levels. MSCs from solid-tissue-derived sources, AT and CT, inhibited T cell proliferation through induction of lymphocyte apoptosis while blood-derived MSCs, BM and CB, induced lymphocyte cell cycle arrest. Equine MSCs from different tissue sources modulated immune cell function by both overlapping and unique mechanisms. MSC tissue source may determine immunomodulatory properties of MSCs and may have very practical implications for MSC selection in the application of MSC therapy.
Get full access to this article
View all access options for this article.
References
1.
JiangY, JahagirdarBN, ReinhardtRL, SchwartzRE, KeeneCD, Ortiz-GonzalezXR, ReyesM, LenvikT, LundT, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418:41–49.
2.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
3.
VoswinkelJ, FrancoisS, SimonJ-M, BenderitterM, GorinN-C, MohtyM, FouillardL and ChapelA. (2013). Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clin Rev Allergy Immunol, 45:180–192.
4.
KernS, EichlerH, StoeveJ, KlüterH and BiebackK. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
5.
TroyerDL and WeissML. (2008). Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells, 26:591–599.
6.
SchuhEM, FriedmanMS, CarradeDD, LiJ, HeekeD, OysermanSM, GaluppoLD, LaraDJ, WalkerNJ, et al. (2009). Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilical-cord blood. Am J Vet Res, 70:1526–1535.
7.
VidalMA, KilroyGE, LopezMJ, JohnsonJR, MooreRM and GimbleJM. (2007). Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg, 36:613–622.
8.
ToupadakisCA, WongA, GenetosDC, CheungWK, BorjessonDL, FerraroGL, GaluppoLD, LeachJK, OwensSD and YellowleyCE. (2010). Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue. Am J Vet Res, 71:1237–1245.
9.
SmithRKW, KordaM, BlunnGW and GoodshipAE. (2003). Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J, 35:99–102.
10.
VidalMA, RobinsonSO, LopezMJ, PaulsenDB, BorkhseniousO, JohnsonJR, MooreRM and GimbleJM. (2008). Comparison of chondrogenic potential in equine mesenchymal stromal cells derived from adipose tissue and bone marrow. Vet Surg, 37:713–724.
11.
BarryFP and MurphyJM. (2004). Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol, 36:568–584.
12.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS and GianniAM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
13.
BarminkoJ, GrayA, MaguireT, SchlossR and YarmushML. (2013). Mesenchymal stromal cell mechanisms of immunomodulation and homing. In: Mesenchymal Stem Cell Therapy. ChaseLG, VemuriMC, and TurksenK, eds. Humana Press, New York, pp 15–38.
14.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
15.
CarradeDD and BorjessonDL. (2013). Immunomodulation by mesenchymal stem cells in veterinary species. Comp Med, 63:1–11.
16.
CarradeDD, LameMW, KentMS, ClarkKC, WalkerNJ and BorjessonDL. (2012). Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med, 4:1–11.
17.
RasmussonI, RingdénO, SundbergB and Le BlancK. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305:33–41.
18.
NautaAJ and FibbeWE. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110:3499–3506.
19.
SatoK, OzakiK, OhI, MeguroA, HatanakaK, NagaiT, MuroiK and OzawaK. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109:228–234.
20.
GlennieS, SoeiroI, DysonPJ, LamEW-F and DazziF. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105:2821–2827.
21.
PlumasJ, ChaperotL, RichardMJ, MolensJP, BensaJC and FavrotMC. (2005). Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia, 19:1597–1604.
22.
BartholomewS, OwensSD, FerraroGL, CarradeDD, LaraDJ, LibrachFA, BorjessonDL and GaluppoLD. (2009). Collection of equine cord blood and placental tissues in 40 thoroughbred mares. Equine Vet J, 41:724–728.
23.
CarradeDD, OwensSD, GaluppoLD, VidalMA, FerraroGL, LibrachF, BuerchlerS, FriedmanMS, WalkerNJ and BorjessonDL. (2010). Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy, 13:419–430.
24.
VidalM, WalkerNJ, NapoliE and BorjessonDL. (2011). Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue and umbilical cord tissue. Stem Cells Dev, 21:273–283.
25.
FrisbieDD, Al-SobayilF, BillinghurstRC, KawcakCE and McIlwraithCW. (2008). Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis Cartilage, 16:1196–1204.
26.
McFarlaneD and HolbrookTC. (2008). Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. J Vet Intern Med, 22:436–442.
27.
BurtonAB, WagnerB, ErbHN and AinsworthDM. (2009). Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals. Vet Immunol Immunopathol, 132:122–128.
28.
GoodmanWA, YoungAB, McCormickTS, CooperKD and LevineAD. (2011). Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol, 186:3336–3345.
29.
KimuraA and KishimotoT. (2010). IL-6: regulator of Treg/Th17 balance. Eur J Immunol, 40:1830–1835.
30.
WangD, JiYR, ChenK, DuWT, YangZX, HanZB, ChiY, LiangL, BayardF and HanZC. (2012). IL-6 production stimulated by CD14+ monocytes-paracrined IL-1β does not contribute to the immunosuppressive activity of human umbilical cord mesenchymal stem cells. Cell Physiol Biochem, 29:551–560.
31.
AkiraS, HiranoT, TagaT and KishimotoT. (1990). Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J, 4:2860–2867.
32.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines andnitric oxide. Cell Stem Cell, 2:141–150.
33.
GhannamS, BouffiC, DjouadF, JorgensenC and NoelD. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther, 1:2.
34.
WinkDA, HinesHB, ChengRYS, SwitzerCH, Flores-SantanaW, VitekMP, RidnourLA and ColtonCA. (2011). Nitric oxide and redox mechanisms in the immune response. J Leuk Biol, 89:873–891.
35.
HsuW-T, LinC-H, ChiangB-L, JuiH-Y, WuKK-Y and LeeC-M. (2013). Prostaglandin E2 potentiates mesenchymal stem cell–induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol, 190:2372–2380.
36.
ChenK, WangD, DuWT, HanZ-B, RenH, ChiY, YangSG, ZhuD, BayardF and HanZC. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol, 135:448–458.
37.
SchoenbornJR and WilsonCB. (2007). Regulation of interferon-γ during innate and adaptive immune responses. Advances in Immunology, 96:41–101.
38.
SzodorayP, PappG, HorvathIF, BarathS, SipkaS, NakkenB and ZeherM. (2009). Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol, 157:343–349.
RamasamyR, FazekasovaH, LamEW-F, SoeiroI, LombardiG and DazziF. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83:71–76.
41.
GrouxH, BiglerM, de VriesJE and RoncaroloMG. (1996). Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med, 184:19–29.
42.
PellegriniJD, DeAK, KodysK, PuyanaJC, FurseRK and Miller-GrazianoC. (2000). Relationships between T lymphocyte apoptosis and anergy following trauma. J Surg Res, 88:200–206.
43.
ZhangZ, FuJ, XuX, WangS, XuR, ZhaoM, NieW, WangX, ZhangJ, et al. (2013). Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS, 27:1283–1293.
44.
GougeonML, LecoeurH, DulioustA, EnoufMG, CrouvoiserM, GoujardC, DebordT and MontagnierL. (1996). Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol, 156:3509–3520.
45.
MassanellaM, CurriuM, CarrilloJ, GómezE, PuigJ, NavarroJ, DalmauJ, Martínez-PicadoJ, CrespoM, et al. (2013). Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytom Part A, 83A:648–658.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
